Unexplained weight loss is one of the most alarming symptoms a person can bring to their family doctor, and one of the most frustrating for clinicians to interpret. It can signal cancer, but it can equally reflect thyroid disease, depression, chronic infection, or nothing sinister at all. In English general practice, the usual next step is a blood test, and the decision to refer a patient for urgent cancer investigation often hinges on whether a single result crosses an abnormal threshold. A large new study published in PLOS Medicine suggests that this snapshot approach may be leaving valuable information on the table, and that the direction in which a blood value is moving over years could sharpen the picture considerably.
The research, led by Brian D. Nicholson and colleagues at the University of Oxford, drew on the Clinical Practice Research Datalink, one of the world’s richest repositories of primary care records. The team identified 275,205 adults aged 18 and over who presented to English general practices with unexpected weight loss between January 2000 and December 2018. Within this cohort, 13,798 patients, or 5.0 percent, were subsequently diagnosed with cancer, with the diagnosis confirmed through linkage to the National Cancer Registrations Data. That relatively modest overall cancer rate is precisely the problem clinicians face: for every twenty patients with worrying weight loss, nineteen do not have cancer, yet each one currently triggers the same difficult judgment about whether to investigate further.
The methodological heart of the study lies in its comparison of two ways of reading the same laboratory data. The conventional approach treats the most recent result as a binary signal: a platelet count above the reference range, or an albumin level below it, counts as abnormal and raises suspicion. The alternative approach, tested here, examines the trajectory of each of 26 quantitative blood tests over the one, three, five, and ten years preceding the weight loss, asking not whether a value is abnormal but whether it is drifting in a concerning direction. To capture these trajectories, the researchers used Cox proportional hazards models for single abnormalities and joint models for trends, and they evaluated performance using the area under the receiver operating characteristic curve, or AUC, a standard measure of how well a test separates those with disease from those without.
A crucial refinement ran through the entire analysis: every model was estimated both unadjusted and adjusted for age and sex. This matters because many blood values shift systematically with age and differ between men and women, so a haemoglobin level that is perfectly normal for an 80-year-old man might be a red flag in a 40-year-old woman. The adjustment consistently improved discrimination for both abnormalities and trends. Indeed, adjusted blood test abnormalities and trends were more discriminative than their unadjusted equivalents across the board, a finding with immediate practical relevance for how reference ranges are applied at the point of care.
The headline result is that trends beat single thresholds most of the time once age and sex were taken into account. Adjustment resulted in higher AUCs for the trend compared with the equivalent blood test abnormality on 34 occasions, with the highest AUC reaching 0.82 (95 percent confidence interval 0.81 to 0.83). In clinical prediction terms, an AUC of 0.82 represents useful, though not definitive, discrimination, meaning the model ranked a randomly chosen cancer patient above a randomly chosen non-cancer patient roughly 82 percent of the time. For a cheap, routinely collected set of laboratory values, that level of performance is noteworthy, particularly in a symptom as non-specific as weight loss.
The site-specific findings add texture to the overall picture. Trends in mean cell volume, a measure of the average size of red blood cells, improved discrimination for bowel cancer and lymphoma. White blood cell count and neutrophil trends carried signal for lung cancer, consistent with the systemic inflammation that often accompanies solid tumours. For prostate cancer, trends in aspartate aminotransferase, red blood cell count, haematocrit, and the platelet-to-lymphocyte ratio all outperformed the corresponding single abnormality. These patterns make biological sense: cancers can remodel blood chemistry slowly over months or years, and a value that has slid steadily toward the edge of the normal range may be more telling than one that sits just inside it on a single occasion.
The sheer scale of routine testing in primary care made the analysis feasible. Among the cohort, the median number of blood tests per person over the ten-year window ranged from two for some test types to four for others, with interquartile ranges stretching from two to twelve tests depending on the analyte. The median interval between a patient’s first and last blood test was 5.2 years for those later diagnosed with cancer and 4.3 years for those who remained cancer-free. Critically, the last test before weight loss typically occurred close to the presentation itself, a median of 0.1 years beforehand in cases and 0.3 years in non-cases, meaning the trend information was genuinely available to the GP at the moment the decision to refer had to be made.
The authors are candid about the limitations of their modelling strategy. Because the study was retrospective and observational, it could not fully account for bias in who was tested; patients who receive frequent blood tests differ systematically from those who do not, often because they already have chronic conditions or concerning symptoms, and this selection can distort apparent associations. The trend analysis was also restricted to patients with at least two results within each trend window, which excludes people with sparse testing histories and may limit how the findings generalise to the least well-monitored patients. Discrimination, moreover, is only one dimension of a diagnostic tool; calibration, clinical utility, and the downstream consequences of more referrals all require prospective evaluation before any change to guidelines.
Even with those caveats, the implications for primary care are concrete. The first and most actionable message is that blood test abnormalities accompanying unexpected weight loss should be interpreted after adjustment for age and sex, since this alone improved discrimination without requiring any new data collection. The second message is that electronic health records already contain the longitudinal data needed to compute trends, and for a meaningful set of test-cancer combinations those trends add discrimination beyond a single threshold. In health systems where decades of laboratory results sit in searchable databases, algorithms that read the trajectory rather than the snapshot could be built into existing clinical software.
For patients, the study offers a reason to feel that the humble full blood count and its chemical cousins hold more diagnostic power than traditionally assumed. Unexpected weight loss will always demand careful clinical judgment, and no blood test pattern can replace that. But as machine-readable histories grow longer and statistical models grow more refined, the difference between a single abnormal value and a decade of drifting values may become the difference between catching a cancer early and catching it late. This study, grounded in nearly three decades of English primary care data, provides the strongest evidence yet that when it comes to blood tests and cancer, the trend is the thing.
Subject of Research: Blood test trends versus single threshold abnormalities for detecting undiagnosed cancer in primary care patients with unexpected weight loss
Article Title: Blood test trend versus single threshold abnormality to discriminate cancer from non-cancer in patients with unexpected weight loss: A retrospective cohort study
Article References: Nicholson, B. D., Bankhead, C. R., Zhu, S., Oke, J. L., Wright Drakesmith, C., Perera, R., Hobbs, F. D. R., & Virdee, P. S. (2026). Blood test trend versus single threshold abnormality to discriminate cancer from non-cancer in patients with unexpected weight loss: A retrospective cohort study. PLOS Medicine, 23(9), e1004956. https://doi.org/10.1371/journal.pmed.1004956
Image Credits: AI Generated
DOI: 10.1371/journal.pmed.1004956
Keywords: unexpected weight loss, cancer diagnosis, primary care, blood tests, retrospective cohort study, Clinical Practice Research Datalink, diagnostic discrimination, AUC, PLOS Medicine, early detection, laboratory medicine, joint models
News Source: Ophelia Keating. (October 9, 2026). Blood Test Trends Outperform Single Abnormalities in Flagging Hidden Cancer After Weight Loss. Scienmag.
